论文部分内容阅读
目的观察门冬氨酸钾镁治疗冠心病心衰的作用。方法随机将128例充血性心力衰竭(CHF)患者分为治疗组62例和对照组66例,对照组应用常规治疗,治疗组在常规治疗基础上口服门冬氨酸钾镁,观察治疗3月后两组心脏超声结果、心功能级别和6分钟步行距离。结果治疗12周后治疗组6min步行距离较对照组增加(P<0.05)心功能分级情况较对照组改善(P<0.05)。结论常规治疗心力衰竭药物的基础上加用门冬氨酸钾镁可进一步改善6min的步行距离和心功能分级。
Objective To observe the effect of potassium and magnesium aspartate in the treatment of heart failure of coronary heart disease. Methods A total of 128 patients with congestive heart failure (CHF) were randomly divided into treatment group (62 cases) and control group (66 cases). The control group was treated with conventional therapy. The treatment group was given oral potassium and magnesium aspartate on the basis of routine treatment, After two sets of echocardiographic results, cardiac function levels and 6-minute walking distance. Results After 12 weeks of treatment, the walking distance of the treatment group was significantly higher than that of the control group (P <0.05). The grading of cardiac function in the treatment group was better than that of the control group (P <0.05). Conclusion The routine treatment of heart failure drugs based on the use of potassium and magnesium aspartate can further improve the 6min walking distance and cardiac function classification.